Question 1

Purpose of the Test

Accepted Answer

Determine patient eligibility for immunotherapy drugs. Predict the likelihood of tumor response to modern treatments. Personalize a precise treatment plan for each cancer patient.

Question 2

Target Groups

Accepted Answer

Patients with non-small cell lung cancer (NSCLC). Individuals with bladder or kidney cancer. Patients with triple-negative breast cancer.

Question 3

Clinical Importance

Accepted Answer

Helps avoid ineffective treatments and their side effects. Provides vital information for informed clinical decision-making. Serves as a cornerstone in personalized oncology medicine.

Guide to Effective Cancer Immunotherapy - PD-L1 Protein Expression Testing (IHC)